🔗 Share this article

Ministers and senior MPs have issued warnings that the United Kingdom's negotiated accords with the US administration are "fundamentally unstable." This stems from revelations that a much-touted deal on medicines, which pledges zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond broad headline terms contained within government press releases.

An Agreement in Principle Only

The US-UK pharmaceuticals agreement, hailed as a "significant" achievement, exists as an "statement of intent" without a signed legal text. Critics have noted that the press releases from the UK and US governments present the deal in divergent terms. The British version focuses on securing "duty-free access" as a singular success, while the American announcement dwells on the expectation for the NHS to pay 25% more for new medications.

"The danger exists that the UK government has promised concessions to increase medicine costs in return for little more than a assurance from President Trump," commented David Henig, a trade policy analyst. "History shows he has a record of not following through on agreements."

Wider Concerns Amidst a Suspended Agreement

Worries have been heightened by Washington's recent decision to suspend the major technology agreement, which was previously described as "a transformative pact" in the bilateral relationship. The US claimed a failure to advance from the UK on addressing wider trade issues as the reason for the pause.

Additionally, concessions secured for British farmers as part of an May trade agreement have not been formally approved by the US, despite a imminent January deadline. "Our understanding is that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

Privately, ministers have voiced worries that the government's agreements with the US are unstable and unpredictable. One minister was quoted as stating the series of agreements as "resting on shaky ground," while another framed the situation as the "prevailing condition" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, argued: "What is even more astonishing than the administration's tactics is the UK government's optimistic assumption that his administration is a reliable partner. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Ministry sources have sought to reduce the risk of the US reneging on the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been lobbying for the agreement, desiring stability on imports and pricing, making it less abstract than the paused tech deal.

Officials concede that volatility is a feature of dealing with the Trump administration. However, they maintain that the UK has achieved real benefits for businesses, such as lower steel tariffs compared to other nations. "The fact we have 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a solid gain," one official said.

Nevertheless, problems have surfaced in enacting the May tariff agreement. Promised quotas on beef exports have yet to be finalized, and the commitment to "reduce steel tariffs to zero" has not been fulfilled, with tariffs remaining at 25%.

As negotiations continue, the two sides have agreed to resume talks on the paused tech prosperity deal in January, following what were described as "constructive" meetings between UK and US officials in Washington.